Madrigal Pharmaceuticals (MDGL) announced six presentations at the upcoming European Association for the Study of the Liver, EASL, Congress, taking place from May 7-10, 2025, in Amsterdam, the Netherlands. Madrigal will share detailed two-year data from the open-label compensated MASH cirrhosis arm of the Phase 3 MAESTRO-NAFLD-1 trial in a late-breaking oral presentation titled, “Treatment with resmetirom for up to two years led to improvement in liver stiffness, fibrosis biomarkers, fibrosis scores and portal hypertension risk in 122 patients with compensated MASH cirrhosis.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- MDGL Earnings this Week: How Will it Perform?
- Madrigal Pharmaceuticals’ Rezdiffra: A Promising First-Mover in MASH Treatment with Strong Growth Potential
- Madrigal Pharmaceuticals Announces Leadership Transition
- Madrigal announces Taub to become Senior Scientific, Medical Advisor
- Madrigal Pharmaceuticals management to meet with Oppenheimer